Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00405782 · ClinicalTrials.gov registry record · NA

Exercise Intervention in Women With Metastatic Breast Cancer

A NA study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
101
Enrollment target
2
Study locations

NCT00405782: Completed NA study of Breast Cancer, sponsored by Dana-Farber Cancer Institute.

NCT00405782 is a NA study of Breast Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 101 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00405782, a NA study of Breast Cancer, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
101 participants
Enrollment target
2
Study locations

Study Summary

This study is being done to evaluate the impact of moderate-intensity exercise (such as walking) on quality of life, energy level, endurance and mood in women with metastatic breast cancer. Studies have shown that women with early stage breast cancer who exercise during treatment have more energy, less sleep disturbance, less anxiety and depression, and better strength and endurance than women who do not exercise. These studies have also shown that women who exercised during treatment for early stage breast cancer did not develop injuries or increased fatigue from exercising during chemotherapy and radiation treatments. The investigators are conducting this trial to see if women with metastatic breast cancer experience similar benefits from exercise as women with earlier breast cancer. The investigators also wish to determine whether women with advanced disease are able to exercise safely during their treatment under the supervision of an exercise physiologist.

Conditions Studied

Interventions

  • BEHAVIORAL Moderate-Intensity Exercise

Study Locations (2)

Massachusetts

  • Beth Isreal Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2006-08
Est. Completion 2016-04
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT00405782 record still lists

NCT00405782 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Moderate-Intensity Exercise is the first listed.

NCT00405782 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00405782 about?

NCT00405782 is a clinical study titled "Exercise Intervention in Women With Metastatic Breast Cancer". This study is being done to evaluate the impact of moderate-intensity exercise (such as walking) on quality of life, energy level, endurance and mood in women with metastatic breast cancer. Studies have shown that women with early stage breast cancer who exercise during treatment have more energy, l...

What is the current status of trial NCT00405782?

This trial is currently completed. It is a NA study. The enrollment target is 101 participants. The study started on 2006-08. Estimated completion is 2016-04.

What conditions does trial NCT00405782 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00405782?

The interventions under investigation include: Moderate-Intensity Exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT00405782?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00405782 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00405782's enrollment target sits among peer trials

101 562nd of 1224 higher than 661 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04033497 · 101 participants · NA

    Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

  • NCT05111574 · 101 participants · Phase 2

    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  • NCT05984680 · 101 participants

    COPD Care Pathway Among Patients With Cancer

  • NCT06266299 · 101 participants · Phase 1

    A Study of KK2269 in Adult Participants With Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00405782, the US trial registry maintained by the National Library of Medicine. NCT00405782 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.